Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 717

1.

OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX.

Oparil S, Calhoun DA, Ghazi L, Dudenbostel T.

J Hypertens. 2016 Sep;34 Suppl 1:e393. doi: 10.1097/01.hjh.0000501006.08047.72.

PMID:
27643186
2.

SY 11-3 HYPERTENSION IN WOMEN: MORE DANGEROUS THAN IN MEN?

Oparil S.

J Hypertens. 2016 Sep;34 Suppl 1:e366. doi: 10.1097/01.hjh.0000500943.95477.bd.

PMID:
27643118
3.

OS 24-04 A PILOT STUDY ASSESSING THE FEASIBILITY OF VASCULAR FUNCTION IN LOW SOCIOECONOMIC STATUS PRESCHOOL CHILDREN.

Ghazi L, Dudenbostel T, Ejem D, Turner-Henson A, Joiner CI, Affuso O, Azuero A, Calhoun DA, Rice M, Hage F, Oparil S.

J Hypertens. 2016 Sep;34 Suppl 1:e244. doi: 10.1097/01.hjh.0000500547.59480.0a.

PMID:
27643050
4.

Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to < 120/80 mmHg Target?: A Protagonist View from SPRINT.

Oparil S, Lewis CE.

Circulation. 2016 Sep 12. pii: CIRCULATIONAHA.116.023263. [Epub ahead of print]

PMID:
27619922
5.

Cardiovascular care for older adults: hypertension and stroke in the older adult.

Miller AP, Navar AM, Roubin GS, Oparil S.

J Geriatr Cardiol. 2016 Jul;13(5):373-9. doi: 10.11909/j.issn.1671-5411.2016.05.001. No abstract available.

6.

Blood Pressure in 2016: increased impact factor and change of editors.

Kjeldsen SE, Narkiewicz K, Oparil S.

Blood Press. 2016 Sep 3:1-2. [Epub ahead of print] No abstract available.

PMID:
27592522
7.

The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale.

Saddekni MB, Saag KG, Dudenbostel T, Oparil S, Calhoun DA, Sattui SE, Feig DI, Muntner P, Redden DT, Foster PJ, Rahn EJ, Biggers SR, Li P, Gaffo AL.

Contemp Clin Trials. 2016 Sep;50:238-44. doi: 10.1016/j.cct.2016.08.016. Epub 2016 Aug 30.

PMID:
27587282
8.

BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?

Bhatt H, Ghazi L, Calhoun D, Oparil S.

Curr Cardiol Rep. 2016 Oct;18(10):98. doi: 10.1007/s11886-016-0775-0. Review.

PMID:
27566331
9.

Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.

Dudenbostel T, Ghazi L, Liu M, Li P, Oparil S, Calhoun DA.

Hypertension. 2016 Oct;68(4):995-1003. doi: 10.1161/HYPERTENSIONAHA.116.07806. Epub 2016 Aug 15.

PMID:
27528066
10.

HOPE-3 and SPRINT: two landmark trials with different outcomes?

Kostis JB, Oparil S.

J Am Soc Hypertens. 2016 Jun;10(6):477-81. doi: 10.1016/j.jash.2016.04.008. Epub 2016 Apr 29. No abstract available.

PMID:
27292823
11.

The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Kronish IM, Lynch AI, Oparil S, Whittle J, Davis BR, Simpson LM, Krousel-Wood M, Cushman WC, Chang TI, Muntner P.

Hypertension. 2016 Jul;68(1):39-45. doi: 10.1161/HYPERTENSIONAHA.115.06960. Epub 2016 May 23.

PMID:
27217410
12.

Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.

Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT Jr, Pajewski NM; SPRINT Research Group.

JAMA. 2016 Jun 28;315(24):2673-82. doi: 10.1001/jama.2016.7050.

PMID:
27195814
13.

Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement.

Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D.

J Am Soc Hypertens. 2016 Jun;10(6):493-9. doi: 10.1016/j.jash.2016.03.186. Epub 2016 Mar 30.

PMID:
27129931
14.

Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial.

Kario K, Bhatt DL, Kandzari DE, Brar S, Flack JM, Gilbert C, Oparil S, Robbins M, Townsend RR, Bakris G.

Circ J. 2016 May 25;80(6):1404-12. doi: 10.1253/circj.CJ-16-0035. Epub 2016 Apr 26.

15.

Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure.

Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA.

Hypertension. 2016 Jun;67(6):1085-92. doi: 10.1161/HYPERTENSIONAHA.116.06587. Epub 2016 Apr 18. No abstract available.

PMID:
27091893
16.

The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease.

Hedner T, Kjeldsen SE, Narkiewicz K, Oparil S.

Blood Press. 2016 Oct;25(5):276-9. doi: 10.3109/08037051.2016.1139324. Epub 2016 Apr 13. No abstract available.

PMID:
27071504
17.

Regional Heterogeneity in 3D Myocardial Shortening in Hypertensive Left Ventricular Hypertrophy: A Cardiovascular CMR Tagging Substudy to the Life Study.

Biederman RW, Young AA, Doyle M, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia LJ.

J Biomed Sci Eng. 2015 Mar 1;8(3):213-225. Epub 2015 Mar 26.

18.

CardioPulse. The SPRINT trial results.

Oparil S.

Eur Heart J. 2016 Mar 21;37(12):924-7. doi: 10.1093/eurheartj/ehw016. No abstract available.

PMID:
27002139
19.

Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults.

Tamura MK, Pajewski NM, Bryan RN, Weiner DE, Diamond M, Van Buren P, Taylor A, Beddhu S, Rosendorff C, Jahanian H, Zaharchuk G; SPRINT Study Research Group.

Neurology. 2016 Mar 29;86(13):1208-16. doi: 10.1212/WNL.0000000000002527. Epub 2016 Feb 26.

PMID:
26920359
20.

Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.

Whittle J, Lynch AI, Tanner RM, Simpson LM, Davis BR, Rahman M, Whelton PK, Oparil S, Muntner P.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):471-80. doi: 10.2215/CJN.04660415. Epub 2016 Feb 18.

PMID:
26912544
Items per page

Supplemental Content

Loading ...
Write to the Help Desk